Pharmacological approaches to the management of alcohol addiction

European Review for Medical and Pharmacological Sciences

Volumn 6, Issue 5, 2002, Pages 89-97

  Addolorato, G ^a   Armuzzi, A ^a   Gasbarrini, G ^a   De Lorenzi, A V ^b   Ancona, C ^b   Abenavoli, L ^b   Parente, A ^b   Leggio, L ^b   Capristo, E ^c   Greco, A V ^c   Janiri, L ^d   Pozzi, G ^d   Taranto, C ^d   Caputo, F ^a   Bernardi, M ^a   Stefanini, G F ^e   Foschi, F G ^e  

^a CATHOLIC UNIVERSITY   (Italy)

^b Institute of Legal Medicine   (Italy)

^c Metabolic Disease Section   (Italy)

^d Institute of Psichiatry   (Italy)

^e Ospedale per gli Infermi di Faenza   (Italy)

Author keywords

Acamprosate; Acute alcohol intoxication; Alcohol withdrawal syndrome; Alcoholism; Baclofen; Benzodiazepine; Craving; Disulfiram; Gamma hydroxybutyric; Naltrexone; Relapse prevention; Serotonin reuptake inhibitor

Indexed keywords

4 HYDROXYBUTYRIC ACID; ACAMPROSATE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BUSPIRONE; CHLORDIAZEPOXIDE; CITALOPRAM; DIAZEPAM; DISULFIRAM; DROPERIDOL; FLUMAZENIL; FLUOXETINE; FOLIC ACID DERIVATIVE; HALOPERIDOL; METADOXINE; METHADONE; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; S ADENOSYLMETHIONINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIAMINE; THIORIDAZINE; TIAPRIDE; UNINDEXED DRUG; VITAMIN;

ALCOHOL ABUSE; ALCOHOL INTOXICATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY DISORDER; COMA; CONTROLLED STUDY; DELIRIUM TREMENS; DRUG ALCOHOL INTERACTION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPOREFLEXIA; INSOMNIA; NAUSEA; RELAPSE; REVIEW; SOMNOLENCE; TERATOGENICITY; VERTIGO; VOMITING; WERNICKE ENCEPHALOPATHY;

ALCOHOL DETERRENTS; ALCOHOL WITHDRAWAL DELIRIUM; ALCOHOLIC INTOXICATION; ALCOHOLISM; HUMANS; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0037648930     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. MCGINNIS JM, FOEGE WH. Actual causes of death in the United States. JAMA 1993; 270: 2207-2212.
2. HUPKENS C, KNIBBE R, DROP M. Alcohol consumption in the European Community: uniformity and diversity in drinking patterns. Addiction 1993; 88: 1391-1404.
3. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association, 1994.
4. SHPILENYA LS, MUZYCHENKO AP, GASBARRINI G, ADDOLORATO G. Metadoxine in acute alcohol intoxication: a double blind randomized placebo controlled study. Alcohol Clin Exp Res 2002; 26: 340-346.
5. MAYO-SMITH MF. Pharmacological management of alcohol withdrawal: A meta-analysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278:144-151.
6. GALLIMBERTI L, CANTON G, GENTILE N, FERRI M, CIBIN M, FERRARA SD, FADDA F, GESSA GL. Gamma-hydroxybutiric acid for the treatment of alcohol withdrawal syndrome. Lancet 1989; ii: 787-789.
7. ADDOLORATO G, BALDUCCI G, CAPRISTO E, ATTILIA ML, TAGGI F, GASBARRINI G, CECCANTI M. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res 1999; 23: 1596-1604.
8. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 2002; 112: 226-229.
9. GARBUTT JC, WEST SL, CAREY T, LOHR, CREWS FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 14: 1318-1325.
10. CAPUTO F, ADDOLORATO G, DALL'AGLIO C, BAUDANZA P, BERNARDI M, GASBARRINI G, STEFANINI GF. Are brief and long-term alcohol intervention really defined? Addiction 1998; 93: 1104.
11. ADDOLORATO G, VIAGGI M, GENTILINI L, CASTELLI E, NICASTRO P, STEFANINI GF, GASBARRINI G. Alcohol addiction: evaluation of the therapeutic effectiveness of self-help group in the maintenance of abstinence from alcohol. Alcologia Eur J Alcohol Stud 1993; 5: 261-263.
12. CIBIN M. Disulfiram, nuove strategie per un "vecchio" farmaco. Medicina delle Tossicodipendenze 1999; 7: 22-23, 57-60.
13. BESSON J, AEBY F, KASAS A, LEHERT P, POTGIETER A. Combined efficacy of Acamprosate and Disulfiram in tre treatment of Alcoholism: a controlled Study. Alcohol Clin Exp Res 1998; 22: 573-579.
14. GASBARRINI G, ADDOLORATO G. Alcohol dependence and craving: physiopathologic, clinical and therapeutic aspects. Italian Rev Med Surg Res 1996; 4: 1-4.
15. GALLIMBERTI L, FERRI M, FERRARA SD, FADDA F, GESSA GL. Gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double blind study. Alcohol Clin Exp Res 1992; 16: 673-676.
16. ADDOLORATO G, CASTELLI E, STEFANINI GF CASELLA G, CAPUTO F, MARSIGLI L, BERNARDI M, GASBARRINI G. An open multicentric study evaluating hydroxybutyric acid sodium salt (GHB) in the medium term treatment of 179 alcohol dependent patients. Alcohol Alcohol 1996; 31: 341-345.
17. ADDOLORATO G, CAPUTO F, CAPRISTO E, STEFANINI GF, GASBARRINI G. Gamma-hydroxybutyric acid: efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol 2002; 20: 217-222.
18. ADDOLORATO G, CAPUTO F, STEFANINI GF, GASBARRINI G. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addiction 1997; 92: 1035-1036.
19. GESSA GL, AGABIO R, CARAI MAM, LOBINA C, PANI M, REALI R, COLOMBO G. Mechanisms of the antialcohol effect of gamma-hydroxylbutyric acid. Alcohol 2000; 20: 271-276.
20. ADDOLORATO G, STEFANINI GF, GASBARRINI G. Manageability and tollerability of Gamma-hidroxybutyric acid in the medium-term outpatient treatment of alcoholism. Alcohol Clin Exp Res 1997; 21: 380.
21. ADDOLORATO G, STEFANINI GF, GASBARRINI G. Patients with alcohol problems. N Engl J Med 1998; 339: 130.
22. ADDOLORATO G, CAPRISTO E, GESSA GL, CAPUTO F, STEFANINI GF, GASBARRINI G. Long term administration of GHB does not affect muscular mass in alcoholics. Life Sci 1999; 65: 191-196.
23. ADDOLORATO G, CAPUTO F, CAPRISTO E, BERNARDI M, STEFANINI GF, GASBARRINI G. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment. Utility of diazepam administration. Clin Neuropharmacol 1999; 22: 60-62.
24. FERRARA SD, ZOTTI S, TEDESCHI L, FRISON G, CASTAGNA F, GALLIMBERTI L, GESSA GL, PALATINI P. Pharmacokinetics of Gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34: 231-235.
25. ADDOLORATO G, CIBIN M, CAPRISTO E, BEGHE F, GESSA G, STEFANINI GF, GASBARRINI G. Maintainig abstinence from alcohol with gamma-hydroxybutyric acid. Lancet 1998; 351: 38.
26. ADDOLORATO G, CIBIN M, CAPUTO F, CAPRISTO E, BEGHE F, GESSA G, STEFANINI GF, GASBARRINI G. Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug Alcohol Depend 1998; 53: 7-10.
27. COLOMBO G, AGABIO R, CARAI MA, LOBINA C, PANI M, REALI R, ADDOLORATO G, GESSA GL. Ability of baclofen in reducing alcohol intake and withdrawal severity: l-preclinical evidence. Alcohol Clin Exp Res 2000; 24: 58-66.
28. COLOMBO G, SERRA S, BRUNETTI G, ATZORI G, PANI M, VACCA G, ADDOLORATO G, FORESTL W, CARAI MAM, GESSA GL. The GABAB receptor agonist baclofen and CGP 44532 prevent acquisition of alcohol drinking behavior in alcohol preferring rats. Alcohol Alcohol 2002; 37: 499-503.
29. COLOMBO G, SERRA S, BRUNETTI G, VACCA G, CARAI MAM, GESSA GL. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend, 2003 (in press).
30. ADDOLORATO G, CAPUTO F, CAPRISTO E, COLOMBO G, GESSA GL, GASBARRINI G. Ability of baclofen in reducing alcohol craving and intake: II-preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 67-71, 200.
31. ADDOLORATO G, CAPUTO F, CAPRISTO E, DOMENICALI M, BERNARDI M, JANIRI L, AGABIO R, COLOMBO G, GESSA GL, GASBARRINI G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-508.
32. VOLPICELLI JR. Naltrexone in alcohol dependence. Lancet 1995; 346: 456.
33. VOLPICELLI JR, ALTERMAN AL, HAYASHIDA M, O'BRIEN CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80.
34. ANTON RF, MOAK DH, WAID LR, LATHAM PK, MALCOLM RJ, DIAS JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156: 1758-1764.
35. O'MALLEY, SS, JAFFE AJ, CHANG G, SCHOTTENFELD R, MEYER RE, ROUNSAVILLE B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992; 49: 881-887.
36. CAPUTO F, ADDOLORATO G, LORENZINI F, DOMENICALI M, GRECO G, DEL RE A, GASBARRINI G, STEFANINI GF, BERNARDI M. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend 2003 (in press).
37. MONTI PM, ROHSENOW DJ, HUTCHISON KE, SWIFT RM, MUELLER TI, COLBY SM, BROWN RA, GULLIVER SB, GORDON A, ABRAMS DB. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386-1394.
38. DAVIDSON D, SWIFT R, FITZ E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 1996; 20: 732-739.
39. PALFAI T, DAVIDSON D, SWIFT R. Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies. Exp Clin Psychopharmacol 1999; 7: 266-273.
40. KRANZLER HR, TENNEN H, PENTA C, BOHN MJ. Targeted naltrexone treatment of early problem drinkers. Addict Behav 1997; 22: 431-436.
41. KRANZLER HR, VAN KIRK J. Efficacy of naltrexone and acamprosate for alcopholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-1341.
42. KRYSTAL JH, CRAMER JA, KRAL WF, KIRK GF, ROSENBECK RK. Naltrexone in the treatment of alcohol dependence. New Engl J Med 2001; 345: 1734-1739.
43. CROOP RS, FAULKNER EB, LABRIOLA DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997; 54: 1130-1135.
44. SASS H, SOYKA M, MANN K, ZIEGLGANSBERGER W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-80.
45. PAILLE FM, GUELFI GB, PERKINS AC, ROYER RJ, STERU L, PAROT P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239-247.
46. PETERS DH, FAULDS D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47: 1010-1032.
47. SHAW GK, WALLER S, MAJUMDAR SK, ALBERTS JL, LATHAM CJ, DUNN G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165: 515-523.
48. GORELICK DA, PAREDES A. Effect of Fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261-265.
49. CORNELIUS JR, SALLOUM IM, EHLER JG, JARRETT PJ, CORNELIUS MD, PEREL JM, THASE ME, BLACK A. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700-705.
50. KRANZLER HR, BURLESON JA, KORNER P, DEL BOCA FK, BOHN MJ, BROWN J, LIEBOWITZ N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-397.
51. SELLERS EM, TONEATTO T, ROMACH MK, SOMER GR, SOBELL LC, SOBELL MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-885.
52. AGABIO R, COLOMBO G, CARAI MAM, GESSA GL. Novel pharmacotherapies and patents for alcohol abuse and alcoholism 1998-2001. Expert Opin Ther Patents 2001; 11: 1496-1520.
53. MOLEC TS, MOLEC EA, DANGIER M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996; 20: 853-858.
54. FAWCETT J, KRAVITZ HM, MCGUIRE M, EASTON M, ROSS J, PISANI V, FOGG LF, CLARK D, WHITNEY M, KRAVITZ G, JAVAID J, TEAS G. Pharmacological treatment for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 2000; 24: 666-674.
55. OTTOMANELLI G. Methadone patients and alcohol abuse. J Sust Abuse Treat 1999; 16: 113-121.
56. CAPUTO F, ADDOLORATO G, DOMENICALI M, MOSTI A, VIAGGI M, TREVISANI F, GASBARRINI G, BERNARDI M, STEFANINI GF, FOR THE SERVICES FOR ADDICTION TREATMENT. Short-term methadone administration reduces alcohol consumption in non-alcoholic heroin addicts. Alcohol Alcohol 2002; 37: 164-168.
57. CABALLERIA J, PARES A, BRU C, GARCIA PLAZA A, CABALLERIA L, CLEMENTE G, RODRIGO L, RODES J. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized duble-blind, placebo-control trial. Spanish group for the study of alcoholic fatty liver. J Hepatol 1998; 28: 54-60.
58. BONO G, SINFORIANI E, MERLO P, BELLONI G, SOLDATI M, GELSO E. Alcoholic abstinence syndrome: short term treatment with metadoxine. Clin Pharmacol Res 1991; 11: 35-40.
59. STEFANINI GF, ADDOLORATO G, CAPUTO F, BERNARDI M, GASBARRINI G. Treatment of alcoholic fatty liver: is the metabolic affect of metadoxine the only reason for improved liver function? J Hepatology 1999; 30: 739.
60. CIBIN M, GENTILE N, FERRI M. Same is effective in reducing ethanol abuse in an outpatient program for alcoholics. In "Biomedical and Social Aspects of alcohol and alcoholism", AA.VV., Elsevier, New York, 1988.
61. SHAW GK. Detoxification: the use of benzodiazepines. Alcohol Alcoholism 1995; 30: 765-770.
62. GALLANT DM, BISHOP MP, CAMP E TISDALE C. A six-month controlled evaluation of metronidazole (Flagyl) in chronic alcoholic patients. Curr Ther Res 1968; 10: 82-87.
63. NUNES EV, QUINTIN FM. Treating anxiety in patients with alcoholism. J Clin Psychiatry 1995; 56 (Suppl 2): 3-9.
64. COLOMBO G, AGABIO R, LOBINA C, REALI R, ZOCCHI A, FADDA F, GESSA GL. Sardinian alcohol-preferring rats: a genetic animal model of anxiety. Physiol Behav 1995; 57: 1181-1185.
65. DAVIDSON KM. Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status. Br J Psychiatry 1995; 166: 199-204.